ABSK 111
Alternative Names: ABSK-111Latest Information Update: 21 May 2022
At a glance
- Originator Abbisko Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Non-small cell lung cancer
Most Recent Events
- 21 May 2022 3668092 - Added KDM, PD & HE; updated intro & dev line; mechanism retained as per pipeline info
- 08 Apr 2022 Preclinical trials in Non-small cell lung cancer (Monotherapy) in China (unspecified route)
- 08 Apr 2022 Pharmacodynamics data from a preclinical study in Non-small cell lung cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)